IL6 and neoplasm: Given that the cytokine IL-6 is a primary stimulator and inflammatory mediator of STAT3, promoting tumor survival by blocking programmed cell death, treatment with celastrol was shown to inhibit IL-6-induced STAT3 phosphorylation in a time-dependent manner, reducing both constitutive and inducible STAT3 activation 20.